ArticleThe Journal of infectious diseases2007
Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.
Article in The Journal of infectious diseases, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed.
- What goes around comes around: updates in the study ofInfection and immunity · 2026Review
- Genomic, proteolytic, and phenotypic characterization ofMicrobiology spectrum · 2026Article
- Magnesium depletion by Candida albicans unleashes two unusual modes of colistin resistance in Pseudomonas aeruginosa with different fitness costs.PLoS biology · 2026Article
- Biofilm and planktonic lifestyles modulate lipid A structure and inflammatory response in Pseudomonas aeruginosa from people with cystic fibrosis.Scientific reports · 2025Article
- Deep-Learning Driven Identification of Novel Antimicrobial Peptides.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- LpxR and PagL expression in live attenuated auxotrophicFrontiers in cellular and infection microbiology · 2025Article
- Mechanistic Insights into Succinic Acid as an Adjuvant for Ciprofloxacin in TreatingMicroorganisms · 2024Article
- NovelMicrobiology spectrum · 2024Article
- Article
- Unravelling the mechanisms causing murepavadin resistance inFrontiers in cellular and infection microbiology · 2024Article
- Genomic and Functional Characterization of Longitudinal Pseudomonas aeruginosa Isolates from Young Patients with Cystic Fibrosis.Microbiology spectrum · 2023Article
- A Mildly Acidic Environment Alters Pseudomonas aeruginosa Virulence and Causes Remodeling of the Bacterial Surface.Microbiology spectrum · 2023Article
- Heterogeneity of Lipopolysaccharide as Source of Variability in Bioassays and LPS-Binding Proteins as Remedy.International journal of molecular sciences · 2023Review
- Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators.International journal of molecular sciences · 2023Review
- LipidA-IDER to Explore the Global Lipid A Repertoire of Drug-Resistant Gram-Negative Bacteria.Analytical chemistry · 2023Article
- Monoclonal antibodies against lipopolysaccharide protect againstFrontiers in cellular and infection microbiology · 2023Article
- Pseudomonas aeruginosa utilizes the host-derived polyamine spermidine to facilitate antimicrobial tolerance.JCI insight · 2022Article
- Membrane lipid renovation in Pseudomonas aeruginosa - implications for phage therapy?Environmental microbiology · 2022Review
- Lipopolysaccharide detection by the innate immune system may be an uncommon defence strategy used in nature.Open biology · 2022Review
- Adaptation and Evolution of Pathogens in the Cystic Fibrosis Lung.Journal of the Pediatric Infectious Diseases Society · 2022Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Three structural features of lipid A (addition of palmitate [C16 fatty acid], addition of aminoarabinose [positively charged amino sugar residue], and retention of 3-hydroxydecanoate [3-OH C10 fatty acid]) were determined for Pseudomonas aeruginosa isolates from patients with cystic fibrosis (CF; n=86), from the environment (n=13), and from patients with other conditions (n=14). Among P. aeruginosa CF isolates, 100% had lipid A with palmitate, 24.6% with aminoarabinose, and 33.3% retained 3-hydroxydecanoate. None of the isolates from the environment or from patients with other conditions displayed these modifications. These results indicate that unique lipid A modifications occur in clinical P. aeruginosa CF isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.